1. 3223-07-2
2. Melphalan Hcl
3. Alkeran Hydrochloride
4. Cb 3025 Hydrochloride
5. Phenylalanine Mustard Hydrochloride
6. L-sarcolysine Hydrochloride
7. Sarcolysin Hydrochloride, L-
8. Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, Monohydrochloride, L-
9. 1vxp4v453t
10. Cb-3025 Hydrochloride
11. Evomela
12. (2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic Acid;hydrochloride
13. L-phenylalanine Mustard Hydrochloride
14. 4-bis(2-chlorethyl)-amino-l-phenylalanine Hydrochloride
15. Alanine Nitrogen Mustard
16. Alkeran (tn)
17. L-phenylalanine, 4-(bis(2-chloroethyl)amino)-, Monohydrochloride
18. (s)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic Acid Hydrochloride
19. Nsc8806
20. Wln: Qvyz1r Dn2g2g &gh
21. Evomela (tn)
22. Melfalan Hydrochloride
23. Alkeran (glaxosmith)
24. L-alanine, Hydrochloride
25. Unii-1vxp4v453t
26. Schembl41335
27. Chembl1200863
28. Dtxsid60872785
29. L-phenylalanine, Monohydrochloride
30. Mfcd01674304
31. Alanine Nitrogen Mustard Hydrochloride
32. Akos025401785
33. Melphalan Hydrochloride [vandf]
34. Melphalan Hydrochloride [usp-rs]
35. Melphalan Hydrochloride [who-dd]
36. Ac-25549
37. Ai3-26377
38. Melphalan Hydrochloride [orange Book]
39. D08173
40. 223m072
41. Q27252967
42. 4-[bis(2-chloroethyl)-amino]-phenylalanine Hydrochloride
43. 4-[bis(2-chloroethyl)-amino]-l-phenylalanine Hydrochloride
44. L-3-(p-(bis(2-chloroethyl)amino)phenyl)alanine Monohydrochloride
45. L-alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, Hydrochloride
46. L-phenylalanine, 4-(bis(2-chloroethyl)amino)-, Hydrochloride (1:1)
Molecular Weight | 341.7 g/mol |
---|---|
Molecular Formula | C13H19Cl3N2O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 8 |
Exact Mass | 340.051211 g/mol |
Monoisotopic Mass | 340.051211 g/mol |
Topological Polar Surface Area | 66.6 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 265 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:
- multiple myeloma,
- malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),
- acute lymphoblastic and myeloblastic leukemia,
- childhood neuroblastoma,
- ovarian cancer ,
- mammary adenocarcinoma.
Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.
Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:
- Myeloablative conditioning (MAC) treatment in case of malignant haematological diseases
- RIC treatment in case of non-malignant haematological diseases.
L01AA03
LOOKING FOR A SUPPLIER?